Neil Buss

1.1k total citations
17 papers, 655 citations indexed

About

Neil Buss is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Neil Buss has authored 17 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 10 papers in Virology and 3 papers in Molecular Biology. Recurrent topics in Neil Buss's work include HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS Research and Interventions (7 papers). Neil Buss is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS Research and Interventions (7 papers). Neil Buss collaborates with scholars based in Switzerland, United Kingdom and United States. Neil Buss's co-authors include Anitra Fielding, Gary J. Muirhead, Diane Kleinermans, Ronald Gieschke, Jean‐Louis Steimer, Xiaoping Zhang, Indravadan H. Patel, A.G. Renwick, Keith Nieforth and Karin Jorga and has published in prestigious journals such as The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and Toxicology and Applied Pharmacology.

In The Last Decade

Neil Buss

17 papers receiving 620 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Buss Switzerland	13	375	252	130	98	90	17	655
Gregory E. Chittick United States	15	484 1.3×	287 1.1×	198 1.5×	78 0.8×	116 1.3×	18	798
Aurélie Barrail‐Tran France	16	387 1.0×	194 0.8×	112 0.9×	75 0.8×	83 0.9×	35	639
Sara E. Gibbons United Kingdom	9	485 1.3×	330 1.3×	120 0.9×	41 0.4×	125 1.4×	13	594
Michael Lamson United States	12	579 1.5×	398 1.6×	132 1.0×	61 0.6×	140 1.6×	25	842
Patricia Lizak United States	15	296 0.8×	144 0.6×	118 0.9×	69 0.7×	107 1.2×	23	637
Catherine Gillotin France	15	278 0.7×	171 0.7×	90 0.7×	34 0.3×	86 1.0×	26	616
Leonor Pou Spain	17	454 1.2×	118 0.5×	293 2.3×	58 0.6×	157 1.7×	29	900
Katy H. P. Moore United States	16	745 2.0×	393 1.6×	305 2.3×	117 1.2×	120 1.3×	24	1.1k
Monique M. R. de Maat Netherlands	10	431 1.1×	229 0.9×	118 0.9×	26 0.3×	121 1.3×	15	606
Rosa María López Spain	18	534 1.4×	134 0.5×	326 2.5×	103 1.1×	144 1.6×	44	888

Countries citing papers authored by Neil Buss

Since Specialization

Citations

This map shows the geographic impact of Neil Buss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Buss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Buss more than expected).

Fields of papers citing papers by Neil Buss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Buss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Buss. The network helps show where Neil Buss may publish in the future.

Co-authorship network of co-authors of Neil Buss

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Buss. A scholar is included among the top collaborators of Neil Buss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Buss. Neil Buss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Chou, Sunwen, Sophie Alain, Carlos Cervera, et al.. (2023). Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases. 229(2). 413–421. 42 indexed citations

Mayers, Douglas L., Jain Chung, Veronika Kohlbrenner, et al.. (2006). Seeking Ethical Designs for HIV Clinical Trials in Treatment-Experienced Patients: An Industry Perspective. AIDS Research and Human Retroviruses. 22(11). 1110–1112. 1 indexed citations

Boyd, Mark, Narendra M. Dixit, Umaporn Siangphoe, et al.. (2006). Viral Decay Dynamics in HIV‐Infected Patients Receiving Ritonavir‐Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV‐NAT 012). The Journal of Infectious Diseases. 194(9). 1319–1322. 9 indexed citations

Patel, Indravadan H., Xiaoping Zhang, Keith Nieforth, Miklos Salgo, & Neil Buss. (2005). Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of Enfuvirtide. Clinical Pharmacokinetics. 44(2). 175–186. 59 indexed citations

Ruxrungtham, Kiat, Mark Boyd, S. Eralp Bellibas, et al.. (2004). Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir‐Boosted Saquinavir in HIV‐1‐Infected Patients. The Journal of Clinical Pharmacology. 44(7). 793–802. 20 indexed citations

Boyd, Mark, Xiaoping Zhang, Albert Dorr, et al.. (2003). Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. The Journal of Clinical Pharmacology. 43(12). 1382–1391. 35 indexed citations

Moyle, Graeme, et al.. (2002). Interaction between saquinavir soft‐gel and rifabutin in patients infected with HIV. British Journal of Clinical Pharmacology. 54(2). 178–182. 12 indexed citations

Buss, Neil, et al.. (2001). Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. British Journal of Clinical Pharmacology. 52(3). 255–264. 61 indexed citations

Kline, Mark W., Richard C. Brundage, Courtney V. Fletcher, et al.. (2001). Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. The Pediatric Infectious Disease Journal. 20(7). 666–671. 12 indexed citations

10.

Buss, Neil & Nick Cammack. (2001). Measuring the Effectiveness of Antiretroviral Agents. Antiviral Therapy. 6(1). 1–7. 18 indexed citations

11.

Muirhead, Gary J., et al.. (2000). Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology. 50(2). 99–107. 142 indexed citations

12.

Kilby, J Michael, et al.. (2000). Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults. Antimicrobial Agents and Chemotherapy. 44(10). 2672–2678. 68 indexed citations

13.

Gieschke, Ronald, et al.. (1999). Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive Patients. Clinical Pharmacokinetics. 37(1). 75–86. 85 indexed citations

14.

Honeywell, Richard J., et al.. (1996). All-Trans-Retinoic Acid in Maternal Plasma and Teratogenicity in Rats and Rabbits. Toxicology and Applied Pharmacology. 141(2). 456–472. 21 indexed citations

15.

Buss, Neil, et al.. (1994). The Teratogenic Metabolites of Vitamin A in Women Following Supplements and Liver. Human & Experimental Toxicology. 13(1). 33–43. 45 indexed citations

16.

Buss, Neil, A. G. Renwick, Kirsteen Donaldson, & C F George. (1992). The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers. Toxicology and Applied Pharmacology. 115(2). 199–210. 22 indexed citations

17.

Buss, Neil & A.G. Renwick. (1992). Blood pressure changes and sympathetic function in rats given cyclohexylamine by intravenous infusion. Toxicology and Applied Pharmacology. 115(2). 211–215. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact